DDInter690 DDInter1054
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Diphenhydramine
Diphenhydramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Ethanol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Dopamine
Dopamine {u} (Compound) resembles {v} (Compound) Levodopa
Ethanol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Doxepin
Doxepin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levodopa
Ethanol {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is associated with {v} (Disease) Parkinson's disease
Parkinson's disease {u} (Disease) is palliated by {v} (Compound) Levodopa
Ethanol {u} (Compound) binds {v} (Gene) GABRA1
GABRA1 {u} (Gene) interacts with {v} (Gene) DRD4
DRD4 {u} (Gene) is bound by {v} (Compound) Levodopa
Ethanol {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) regulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Levodopa
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Ethanol {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Isoprenaline
Isoprenaline {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Ethanol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dopamine (Compound) and Dopamine (Compound) resembles Levodopa (Compound)
Ethanol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Doxepin (Compound) and Doxepin may cause a minor interaction that can limit clinical effects when taken with Levodopa
Ethanol (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is associated with Parkinson's disease (Disease) and Parkinson's disease (Disease) is palliated by Levodopa (Compound)
Ethanol (Compound) binds GABRA1 (Gene) and GABRA1 (Gene) interacts with DRD4 (Gene) and DRD4 (Gene) is bound by Levodopa (Compound)
Ethanol (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) regulates PCNA (Gene) and PCNA (Gene) is downregulated by Levodopa (Compound)
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Levodopa
Ethanol (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Isoprenaline (Compound) and Isoprenaline (Compound) resembles Levodopa (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Levodopa